A physiological function for apolipoprotein(a): A natural regulator of the inflammatory response

Experimental Biology and Medicine

Volumn 234, Issue 1, 2009, Pages 28-34

  Hoover Plow, Jane ^a   Hart, Erika ^a   Gong, Yanqing ^a   Shchurin, Aleksey ^a,b   Schneeman, Tracey ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Oakwood Healthcare Inc   (United States)

^c Cleveland Public Schools   (United States)

Author keywords

Apo(a) transgenic mice; Neutrophil recruitment; Plasminogen deficient mice; Thioglycollate and lipopolysaccharide induced peritoneal inflammation

Indexed keywords

APOLIPOPROTEIN A; CHEMOKINE; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LIPOPROTEIN A; MACROPHAGE INFLAMMATORY PROTEIN 2; PLASMIN; PLASMINOGEN; THIOGLYCOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE SYSTEM; IMPLANT; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; PERITONEUM; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS A; CHEMOKINE CXCL2; CYTOKINES; INFLAMMATION; LEUKOCYTES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTROPHILS; PLASMINOGEN;

MUS; MUS MUSCULUS;

EID: 60549101700     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0804-RM-136     Document Type: Article

References (54)

1. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 59:369-382, 1963.
2. Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipoprotein(a): isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem 259:11470-11478, 1984.
3. Rhodes GG, Dahién GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 256:2540-2544, 1986.
4. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 91:948-950, 1995.
5. Groves P, Rees A, Bishop A, Morgan R, Ruttley M, Lewis N, Lane I, Hall R. Apolipoprotein(a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease. Br Heart J 69:26-30, 1993.
6. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease-meta-analysis of prospective studies. Circulation 102:1082-1085, 2000.
7. Nachman RL, Gavish D, Azrolan N, Clarkson TB. Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. Arteriosclerosis 11: 32-38, 1991.
8. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TM, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at reoperation. Arteriosclerosis 9: 593-603, 1989.
9. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360:670-672, 1992.
10. Svindland A, Berg K, Eliassen K, Lawn RM, Djurovic S, Aleström P, Noren T, Smith A. Histopathology of arterial lesions in LPA transgenic mice on cholesterol-enriched chow. Atherosclerosis 153:349-354, 2000.
11. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipopro-tein(a) is homologous to plasminogen. Nature 330:132-137, 1987.
12. Hoover-Plow JL, Miles LA, Fless GM, Scanu AM, Plow EF. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry 32:13681-13687, 1993.
13. Miles LA, Sebald MT, Fless GM, Scanu AM, Curtiss LK, Plow EF, Hoover-Plow JL. Interaction of lipoprotein(a) with the extracellular matrix. Fibrinolysis Proteolysis 12:79-87, 1998.
14. Miles LA, Fless GM, Scanu AM, Baynham P, Sebald MT, Skocir P, Curtiss LK, Levin EG, Hoover-Plow JL, Plow EF. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 73:458-465, 1995.
15. Fan J, Shimoyamada H, Sun H, Marcovina S, Honda K, Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 21:88-94, 2001.
16. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 100:558-564, 1997.
17. Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM. Lipoprotein(a) vascular accumulation in mice-in vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 100:1493-1500, 1997.
18. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipo-protein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Med 1:256-259, 1995.
19. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-b is inhibited in transgenic apolipopro- tein(a) mice. Nature 370:460-462, 1994.
20. Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 217:31367-31371, 1996.
21. Sha J, McCullough B, Hart E, Nassir F, Davidson NO, Hoover-Plow J. Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. J Thromb Haemost 3:2281-2289, 2005.
22. Lawn RM, Boonmark NW, Schwartz K, Lindahl GE, Wade DP, Byrne CD, Fong KJ, Meer K, Patthy L. The recurring evolution of lipoprotein(a)-insights from cloning of hedgehop apolipoprotein(a). J Biol Chem 270:24004-24009, 1995.
23. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 91:2005-2009, 1998.
24. Busuttil SJ, Ploplis VA, Castellino FJ, Tang L, Eaton JW, Plow EF. A central role for plasminogen in the inflammatory response to biomaterials. J Thromb Haemost 2:1798-1805, 2004.
25. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem 276:46864-46869, 2001.
26. Haque NS, Fallon JT, Taubman MB, Harpel PC. The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood 97:39-45, 2001.
27. Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 90: 2027-2036, 1997.
28. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene in mice on thrombosis, growth and health. Circulation 92:2585-2593, 1995.
29. Bonen DK, Hausman AML, Hadjiagapiou C, Skarosi SF, Davidson NO. Expression of a recombinant apolipoprotein(a) in HepG2 cells: evidence for intracellular assembly of lipoprotein(a). J Biol Chem 272: 5659-5667, 1997.
30. Fan J, Ji ZS, Huang Y, de Silva H, Sanan D, Mahley RW, Innerarity TL, Taylor JM. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J Clin Invest 101: 2151-2164, 1998.
31. Himmelhoch SR, Evans WH, Mage MG, Peterson EA. Purification of myeloperoxidases from the bone marrow of the guinea pig. Biochemistry 8:914-921, 1969.
32. Torres JL, Rush RS, Main AR. Physical and chemical characterization of a horse serum carboxylesterase. Arch Biochem Biophys 267:271-279, 1988.
33. Tang L, Ugarova TP, Plow EF, Eaton JW. Molecular determinants of acute inflammatory responses to biomaterials. J Clin Invest 97:1329-1334, 1996.
34. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomaterials. J Exp Med 178:2147-2156, 1993.
35. Sharma L, Melis E, Hickey MJ, Clyne CD, Erlich J, Khachigian LM, Davenport P, Morand E, Carmeliet P, Tipping PG. The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia. Am J Pathol 165:331-340, 2004.
36. Cazzola M, Ciaprini C, Page CP, Matera MG. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opin Ther Targets 11:1273-1286, 2007.
37. Ardizzone S, Bianchi PG. Biologic therapy for inflammatory bowel disease. Drugs 65:2253-2286, 2005.
38. Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 17: 612-616, 2005.
39. Morgan BJ. Vascular consequences of intermittent hypoxia. Adv Exp Med Biol 618:69-84, 2007.
40. Simo JM, Joven J, Vilella E, Ribas M, Pujana MA, Sundaram IM, Hammel JP, Hoover-Plow JL. Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease. Thromb Haemost 85:412-1-17, 2001.
41. Linden T, Taddei-Peters W, Wilhelmsen L, Herlitz J, Karlsson T, Ullstrom C, Wiklund O. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 137:175-186, 1998.
42. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 98:2414-2424, 1996.
43. Fortunato JE, Bassiouny HS, Song RH, Kocharian H, Glagov S, Edelstein C, Scanu AM. Apolipoprotein (a) fragments in relation to human carotid plaque instability. J Vasc Surg 32:555-563, 2000.
44. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]. J Lipid Res 37:1786-1801, 1996.
45. Lamanuzzi LB, Mtairag EM, Pepe G, Angles-Cano E. Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a). Thromb Haemost 92: 1066-1075, 2004.
46. McCormick SPA, No JK, Taylor S, Flynn LM, Hammer RE, Young SG. Mutagenesis of the human apoliporotein B gene in a yeast artifacial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci USA 92:10147-10151, 1995.
47. Flesch IE, Barsig J, Kaufmann SH. Differential chemokine response of murine macrophages stimulated with cytokines and infected with Listeria monocytogenes. Int Immunol 10:757-765, 1998.
48. Garcia-Ramallo E, Marques T, Prats N, Beleta J, Kunkel SL, Godessart N. Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol 169: 6467-6473, 2002.
49. Bogen S, Pak J, Garifallou M, Deng X, Muller WA. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med 179:1059-1064, 1994.
50. Tang L, Jiang W, Welty SE. The participation of P- and E-selectins on biomaterial-mediated tissue responses. J Biomed Mater Res 62:471-477, 2002.
51. Segal BH, Kuhns DB, Ding L, Gallin JI, Holland SM. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J Leukoc Biol 71:410-416, 2002.
52. Tang L. Mechanisms of fibrinogen domains: biomaterial interactions. J Biomater Sci Polym Ed 9:1257-1266, 1998.
53. Brodsky JA, Brody FJ, Endlich B, Armstrong DA, Ponsky JL, Hamilton IA. MCP-1 is highly expressed in peritoneum following midline laparotomy with peritoneal abrasion in a murine model. Surg Endosc 16:1079-1082, 2002.
54. Remick DG, Green LB, Newcombe DE, Garg SJ, Bolgos GL, Call DR. CXC chemokine redundancy ensures local neutrophil recruitment during acute inflammation. Am J Pathol 159:1149-1157, 2001.